Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

MANE stock hub

Veradermics, Incorporated has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

MANEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.4B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

MANE

In the news

Latest news · MANE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-72.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-46.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All MANE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

146

Groups with data

Currency

USD

Showing 146 of 146 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001827635
Company name	Veradermics, Incorporated
Country	United States
Country code	US
Cusip	922967104
Enterprise value	$4.2B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-02-04
Isin	US9229671048
Last refreshed	2026-05-10
Market cap	$4.4B
Market cap category	Mid-Cap
Price	$106
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	MANE
Tags	pharmaceuticals
Website	https://www.veradermics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.91%
FCF yield	-1.64%
P/B ratio	30.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-83.4M
Net Income Growth Years	0%
ROA	-43.45
ROCE	-50.43
ROE	-72.06
ROIC	-46.55

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$152.6M
Cash	$141.9M
Current Assets	$152.5M
Current Liabilities	$9.2M
Debt	$4,000
Debt Equity	$0
Equity	$143.5M
Liabilities	$9.2M
Long Term Assets	$125,000
Long Term Liabilities	$4,000
Net Cash	$141.9M
Net Cash By Market Cap	$3.25
Net Debt Equity	$-0.99
Tangible Book Value	$-122.9M
Tangible Book Value Per Share	$-164

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	16.66
Net Working Capital	$1.5M
Quick ratio	15.64
Working Capital	$143.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	69.92
All Time High	117.7
All Time High Change	-9.83%
All Time High Date	2026-05-06
All Time Low	32
All Time Low Change	231.69%
All Time Low Date	2026-02-04
ATR	8.61
Beta1y	-0.38
High	110.8
High52	117.7
High52 Date	2026-05-06
High52ch	-9.83%
Low	105.2
Low52	32
Low52 Date	2026-02-04
Low52ch	231.69%
Ma50ch	51.79%
RSI	66.34
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	3.84x
Sortino ratio	10.04
Tr1m	87.16%
Tr1w	5.09%
Tr3m	175.83%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	3
Analyst Price Target Top	$83.33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.66
Operating Income	$-72.3M
Price target	$83.33
Price Target Change	$-21.49
Price Target Change Top	$-21.49

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,128,106%
Float Percent	63.44%
Shares Insiders	4.08%
Shares Institutions	18.73%
Shares Out	41,183,254
Shares Qo Q	1.74%
Short Float	6.85%
Short Ratio	3.36
Short Shares	4.35

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-73.1M
Average Volume	779,448.6x
Bv Per Share	-163.9
CAPEX	$-24,000
Ch1m	87.16
Ch1w	5.09
Ch3m	175.8
Change	-1.59%
Change From Open	-1.61
Close	107.9
Days Gap	0.03
Dollar Volume	52,678,237.3
Earnings Date	2026-03-30
Earnings Time	bmo
EBIT	$-72.3M
EPS	$-112
F Score	1
FCF	$-71.6M
FCF EV Yield	-1.69x
FCF Per Share	$-1.74
Financing CF	159,142,000
Fiscal Year End	December
Founded	2,019
Investing CF	-118,858,000
Ipr	524.4
Iprfo	212.2
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma20	89.28
Ma20ch	18.89%
Net CF	-31,318,000
Next Earnings Date	2026-08-06
Open	107.9
Optionable	No
Position In Range	16.37
Post Close	106.1
Postmarket Change Percent	-0.45
Postmarket Price	$106
Ppne	125,000
Price Date	2026-05-08
Relative Volume	0.64x
Share Based Comp	1,440,000
Us State	Connecticut
Volume	496,309

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does MANE pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns MANE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+18.7%

Float: +63.4% of shares outstanding

Insider ownership

+4.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

MANE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

66.3

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

3.84

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About MANE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current MANE stock rating?

Veradermics, Incorporated is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MANE analysis?

The full report lives at /stocks/MANE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for MANE?

The latest report frames MANE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the MANE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.